Roche Acquires Telavant for $7.25 Billion to Secure TL1A Antibody RVT-3101

On October 23, Roche announced that it had reached an acquisition agreement with Telavant, a subsidiary of Roivant Sciences, to obtain the rights for the development, manufacturing, and commercialization of Telavant's core investigational product, the TL1A antibody RVT-3101, in the United States and Japan. According to the agreement,Roche to Pay Telavant $7.1 Billion Upfront and $150 Million in Near-Term Milestone Payments.

RVT-3101 is a potential first-in-class drug that exerts its therapeutic effects by inhibiting tumor necrosis factor-like ligand 1A (TL1A), thereby blocking inflammatory and fibrotic pathways. The TL1A antibody possesses dual anti-inflammatory and anti-fibrotic properties, with its primary indication currently being developed for inflammatory bowel disease (IBD).

RVT-3101 was originally co-developed by Telavant, a subsidiary of Roivant, and Pfizer. Telavant is fully responsible for the subsequent development of RVT-3101 and holds the commercialization rights for the drug in the United States and Japan. Pfizer owns 25% of Telavant's shares and holds the commercialization rights for RVT-3101 outside the United States and Japan.

In June 2023, Riovant announced the Phase II TUSCANY-2 study data for RVT-3101 in the treatment of moderate to severe Crohn's disease (UC). The study lasted 56 weeks, with the first 14 weeks as the induction period, followed by a 42-week maintenance treatment period.

The study results showed that at week 56, among all patients who received RVT-3101 during the induction and maintenance phases, the clinical remission rate was 36% (29% at week 14), the endoscopic improvement rate was 50% (36% at week 14), and the endoscopic remission rate was 21% (11% at week 14); in biomarker-positive patients, the clinical remission rate at week 56 was 43% (33% at week 14), the endoscopic improvement rate was 64% (47% at week 14), and the endoscopic remission rate was 36% (13% at week 14). In terms of safety, RVT-3101 was well tolerated at all doses, and no patients developed neutralizing antibodies after treatment.

In April 2023, Merck acquired Prometheus Biosciences for a total transaction value of $10.8 billion, obtaining its core pipeline TL1A antibody PRA023. On October 4, Sanofi reached a co-development collaboration agreement with Teva for the latter's TL1A monoclonal antibody TEV'574, at a total amount exceeding $1.5 billion. This time, Roche has acquired Telavant for a total amount exceeding $7 billion to obtain the TL1A antibody RVT-3101. Thus, TL1A has evidently become a star therapeutic target in the IBD field.

PharmaCube Pro

New Targets, New Technologies, New Therapies

Media Cooperation: 15895423126

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message to the WeChat Official Account's backend or send a message, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.